Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 study of LP-184 (STAR-001) in patients with central nervous system (CNS) indications

Next Previous
Trial Profile

A phase 2 study of LP-184 (STAR-001) in patients with central nervous system (CNS) indications

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Irofulven (Primary)
  • Indications CNS cancer; CNS disorders
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Starlight Therapeutics

Most Recent Events

  • 08 Nov 2023 According to a Lantern Pharma media release, the dosage and safety data obtained in the Phase 1 trial (CTP-700325390) will be used to advance the central nervous system (CNS) indications for a future Phase 2 trial to be sponsored by Starlight Therapeutics.
  • 16 Aug 2023 New trial record
  • 09 Aug 2023 According to a Lantern Pharma media release, Starlight will refer to the molecule LP-184, as it is developed in CNS indications, as ''STAR-001''.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top